In a report published Wednesday, Wedbush Securities analyst Zarak Khurshid reiterated an Outperform rating on Illumina ILMN, and raised the price target from $200.00 to $230.00.
In the report, Wedbush Securities noted, “4Q14 sequencing business [is] even better than the 1/12/15 preannouncement suggested. ILMN reported $512 MM and $0.87 non-GAAP EPS, which topped our initial $497 MM and $0.79 EPS estimate. Consensus estimates were for $506 MM and $0.78. Most of the $0.08 EPS beat was due to tax benefits.”
Illumina closed on Tuesday at $203.25.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in